文献速递复苏、休克与脓毒症消化、代谢与肾脏急症

成人脓毒症抗菌药物耐药风险模型的性能评估

Performance of Risk Models for Antimicrobial Resistance in Adult Patients With Sepsis.
PubMed 文献 · JAMA Netw Open · 2024-11-04
一句话结论在39 893例脓毒症患者中,耐药革兰阴性杆菌预测模型的跨院性能差异与耐药患病率相关(R=0.79),而非患者病例组合,提示使用通用模型需谨慎。

这项回顾性队列研究纳入2016年1月至2021年10月密苏里州和伊利诺伊州10家急症医院的39 893例脓毒症患者(85 238次脓毒症发作),开发社区获得性和医院获得性脓毒症的深度学习模型,预测耐头孢曲松/头孢吡肟革兰阴性杆菌感染。结果显示模型AUROC和AUPRC在不同医院和患者亚组间存在差异,AUPRC与耐药革兰阴性杆菌患病率相关(R=0.79;P=.001)。作者认为模型性能差异与抗菌药物耐药患病率相关而非患者病例组合,使用通用模型预测脓毒症耐药革兰阴性杆菌病因时需谨慎。

要点

  • 在39 893例脓毒症患者中,社区获得性脓毒症RS和RR分别占3.9%(1667次)和1.8%(796次),医院获得性分别占5.7%(2389次)和3.9%(1626次)。
  • 模型AUPRC与耐药革兰阴性杆菌患病率相关(R=0.79;P=.001),提示跨院性能差异主要与局部耐药率有关。
  • 社区获得性脓毒症中,耐药患者RR发作375次(47.1%)、RS发作420次(25.2%),而SS发作3483/40 744次(8.5%)(P<.001),既往感染和抗生素暴露与耐药风险相关。
  • 模型在社区获得性和医院获得性脓毒症中的AUROC和AUPRC在不同医院和患者亚组间存在差异。
  • 作者认为,使用通用模型预测脓毒症耐药革兰阴性杆菌病因时需谨慎。

适用人群与场景

  • 纳入标准:血培养提示脓毒症、接受4天抗生素治疗、存在器官功能障碍(使用血管活性药物、机械通气、肌酐或胆红素升高、血小板减少)的成人患者。
  • 研究场景:密苏里州和伊利诺伊州城乡10家急症医院,2016年1月至2021年10月,社区获得性(就诊时即脓毒症)和医院获得性(入院≥48小时后发生脓毒症)脓毒症。

诊断标准与关键阈值

  • 脓毒症定义:血培养提示脓毒症,且接受4天抗生素治疗并存在器官功能障碍(使用血管活性药物、机械通气、肌酐或胆红素升高、血小板减少)。
  • 耐药分层:头孢曲松敏感革兰阴性杆菌(SS)、头孢曲松耐药但头孢吡肟敏感(RS)、头孢曲松和头孢吡肟均耐药(RR);阴性培养和其他病原体归为SS。
  • 医院获得性脓毒症:入院≥48小时后发生脓毒症。

研究设计与关键结果

  • 研究类型:回顾性队列研究,纳入10家急症医院39 893例患者(85 238次脓毒症发作),其中社区获得性43 207次(50.7%),医院获得性42 031次(48.3%)。
  • 人群特征:中位年龄65(IQR 54-74)岁,男性21 241例(53.2%),18 830例(47.2%)有既往脓毒症发作。
  • 耐药比例:社区获得性脓毒症中RS占3.9%(1667次),RR占1.8%(796次);医院获得性中RS占5.7%(2389次),RR占3.9%(1626次)。
  • 耐药危险因素:既往感染和抗生素暴露与耐药革兰阴性杆菌风险相关;社区获得性脓毒症中,RR发作375次(47.1%)、RS发作420次(25.2%)、SS发作3483/40 744次(8.5%)发生于对抗菌药物耐药的患者(P<.001)。
  • 模型性能:AUROC和AUPRC在不同医院和患者亚组间存在差异;AUPRC与耐药革兰阴性杆菌患病率相关(R=0.79;P=.001)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,模型性能差异与抗菌药物耐药患病率相关而非患者病例组合,使用通用模型预测脓毒症耐药革兰阴性杆菌病因时需谨慎。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The results of prediction models that stratify patients with sepsis and risk of resistant gram-negative bacilli (GNB) infections inform treatment guidelines. However, these models do not extrapolate well across hospitals.

OBJECTIVE: To assess whether patient case mix and local prevalence rates of resistance contributed to the variable performance of a general risk stratification GNB sepsis model for community-onset and hospital-onset sepsis across hospitals.

DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study conducted from January 2016 and October 2021. Adult patients with sepsis at 10 acute-care hospitals in rural and urban areas across Missouri and Illinois were included. Inclusion criteria were blood cultures indicating sepsis, having received 4 days of antibiotic treatment, and having organ dysfunction (vasopressor use, mechanical ventilation, increased creatinine or bilirubin levels, and thrombocytopenia). Analyses were completed in April 2024.

EXPOSURE: The model included demographic characteristics, comorbidities, vital signs, laboratory values, procedures, and medications administered.

MAIN OUTCOMES AND MEASURES: Culture results were stratified for ceftriaxone-susceptible GNB (SS), ceftriaxone-resistant but cefepime-susceptible GNB (RS), and ceftriaxone- and cefepime-resistant GNB (RR). Negative cultures and other pathogens were labeled SS. Deep learning models were developed separately for community-onset (patient presented with sepsis) and hospital-onset (sepsis developed ≥48 hours after admission) sepsis. The models were tested across hospitals and patient subgroups. Models were assessed using area under the receiver operating characteristic curve (AUROC) and area under precision recall curve (AUPRC).

RESULTS: A total of 39 893 patients with 85 238 sepsis episodes (43 207 [50.7%] community onset; 42 031 [48.3%] hospital onset) were included. Median (IQR) age was 65 (54-74) years, 21 241 patients (53.2%) were male, and 18 830 (47.2%) had a previous episode of sepsis. RS contributed to 3.9% (1667 episodes) and 5.7% (2389 episodes) of community-onset and hospital-onset sepsis episodes, respectively, and RR contributed to 1.8% (796 episodes) and 3.9% (1626 episodes), respectively. Previous infections and exposure to antibiotics were associated with the risk of resistant GNB. For example, in community-onset sepsis, 375 RR episodes (47.1%), 420 RS episodes (25.2%) and 3483 of 40 744 (8.5%) SS episodes were among patients with resistance to antimicrobial drugs (P < .001). The AUROC and AUPRC results varied across hospitals and patient subgroups for both community-onset and hospital-onset sepsis. AUPRC values correlated with the prevalence rates of resistant GNB (R = 0.79; P = .001).

CONCLUSIONS AND RELEVANCE: In this cohort study of 39 893 patients with sepsis, variable model performance was associated with prevalence rates of antimicrobial resistance rather than patient case mix. This variability suggests caution is needed when using generalized models for predicting resistant GNB etiologies in sepsis.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Vazquez Guillamet MC, Liu H, Atkinson A, et al. Performance of Risk Models for Antimicrobial Resistance in Adult Patients With Sepsis. JAMA Netw Open. 2024. PMID: 39509131. doi:10.1001/jamanetworkopen.2024.43658

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。